Cellectis S.A.
CLLSHealthcare|Biotechnology|FR
$1.07
+0.04 (+3.88%)
Tangible Book / Share
$0.40
Cash / Share
$1.66
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05607420 Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma | B-cell Non-Hodgkin Lymphoma (B-NHL) | P1P2 | Recruiting | 80 | Open-label | UCART20x22, CLLS52 |
| NCT04150497 Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) | B-cell Acute Lymphoblastic Leukemia | P1P2 | Recruiting | 52 | Open-label | UCART22, CLLS52 |
| NCT03190278 Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Relapsed/Refractory Acute Myeloid Leukemia | P1 | Active | 29 | Open-label | UCART123v1.2 |
| NCT04142619 Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) | Relapsed/Refractory Multiple Myeloma | P1 | Terminated | 11 | Open-label | UCARTCS1A |
| NCT04106076 Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia | Acute Myeloid Leukaemia | P1 | Withdrawn | — | Open-label | UCART123 |
| NCT03203369 Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | P1 | Terminated | 1 | Open-label | UCART123 |